COIOSDeep risk insights through multi-disciplinary research across the globe
A bright stationery store interior with shelves of greeting cards and office supplies
Item confirms Peer-reviewed Added

GLP-1 users with obesity and raised CRP died less often, with heart attacks unchanged

In 50,009 matched pairs with obesity and raised CRP, death, heart attack and stroke combined were lower with GLP-1 exposure (HR 0.80), almost entirely through fewer deaths (HR 0.61).

In TriNetX records, adults with obesity and CRP of 3 to 10 mg/L taking a GLP-1 drug were matched with metformin, orlistat or phentermine users. Over up to ten years, death, heart attack and stroke combined were lower in the 50,009 GLP-1 users (HR 0.80). Fewer deaths accounted for most of that (HR 0.61); heart attacks did not differ, while stroke and arrhythmias were modestly lower.

Why it is interesting: Almost all of the lower composite is fewer deaths, with heart attacks unchanged.

Source
The American Journal of Cardiology, 21 September 2026
Paper
GLP-1 Analogues and Long-term Outcomes in Adults with Obesity and Elevated CRP: A Real-world Matched Cohort Study
Authors
Shah S, Abusafia M, Sheashaa H, Jadam S, Ospina S, Kaelber D et al.
DOI
10.1016/j.amjcard.2026.09.016
Type
Peer-reviewed article
Design
Propensity-matched active-comparator cohort in the TriNetX federated EHR network, 50,009 per arm, followed up to 10 years
Verdict
Confirms prior evidence
Driver
Heart and stroke
Driver
Obesity, diabetes and GLP-1
Free full text
Free to read at the publisher

Other drivers in Health today